Methylomics is a cancer diagnostics company that specializes in cancer diagnosis and monitoring by genome wide methylation profiling. A unique and inexpensive technique called MeD-seq, developed by the founders of Methylomics, helped us to create an extensive DNA methylation cancer atlas. This database can be used for diagnosing and determining the origin of all cancer types. The groundbreaking MeD-seq technology also helped us discover two proprietary pan-gynecological markers (qMSP assay) that can be used for the rapid detection of all types of gynecological cancers at once. 𝐎𝐩𝐩𝐨𝐫𝐭𝐮𝐧𝐢𝐭𝐢𝐞𝐬 • Methylation profiling and marker discovery: Partner with us on innovative research projects aimed at elucidating the role of methylation in cancer and utilize the diagnostic opportunities of specific methylation markers. • Diagnostic assay development service: Collaborate with our experts to develop rapid and inexpensive methylation assays for the detection of specific cancer types • Clinical trials: Join forces in conducting clinical trials to strengthen the clinical utility of methylation sequencing in personalized medicine (diagnosis & treatment monitoring). 𝐖𝐡𝐲 𝐌𝐞𝐭𝐡𝐲𝐥𝐨𝐦𝐢𝐜𝐬? • Scientific Excellence: Our team of experts, comprising of distinguished scientists, bioinformaticians and researchers, are committed to delivering promising results with scientific excellence. • Cutting-Edge technology: We pride ourselves on utilizing the most advanced, versatile, and inexpensive methylation sequencing platform, ensuring accuracy and reliability of our data. • Tailored Solutions: We understand that each research project is unique. As such, we offer custom methylation sequencing services, flexible bioinformatics pipelines and diagnostic assay development to cater to your specific needs. • Timely delivery: We respect the importance of timely results in scientific endeavors. Our streamlined bioinformatics pipeline ensures a promptly delivery of your data.